系统性硬化症相关肺动脉高压的治疗进展
| 作者: |
1朱轩池,
2刘秀梅
1 山西医科大学第一临床医学院，太原 030001 2 山西医科大学第一医院风湿免疫科，太原 030001 |
| 通讯: |
刘秀梅
Email: fsklxm@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.07.037 |
摘要
肺动脉高压(pulmonary arterial hypertension，PAH)是系统性硬化症(systemic sclerosis，SSc)肺部受累最常见的并发症之一，也是SSc患者最主要的死亡原因。近年来，随着各种新型靶向药物的应用以及治疗策略的改进，系统性硬化症相关肺动脉高压(systemic sclerosis-associated pulmonary arterial hypertension，SSc-PAH)患者的生存率有了明显的提升。
关键词：
系统性硬化症相关肺动脉高压；肺血管扩张剂；新型靶向药物；初始联合治疗
Progress in the treatment of systemic sclerosis-associated pulmonary arterial hypertension
CorrespondingAuthor: LIU Xiumei Email: fsklxm@163.com
DOI: 10.3978/j.issn.2095-6959.2021.07.037
Abstract
Pulmonary arterial hypertension (PAH) is one of the most common complications of pulmonary involvement in systemic sclerosis (SSc), and it is also the leading cause of death in patients with SSc. In recent years, with the application of new targeted drugs and the improvement of treatment strategies, the survival rate of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been greatly increased.
Keywords：
systemic sclerosis-associated pulmonary arterial hypertension; pulmonary arterial vasodilator; new targeted drugs; initial combination therapy